TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care
B: Arm Label: High Volume; Type: EXPERIMENTAL; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Arm Label: Medium Volume; Type: ACTIVE_COMPARATOR; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): High Volume | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): Medium Volume
C: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
D: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Arm Label: High Volume; Type: EXPERIMENTAL; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Arm Label: Medium Volume; Type: ACTIVE_COMPARATOR; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): High Volume | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): Medium Volume
B: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
C: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
D: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
B: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
C: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
D: Arm Label: heparin; Type: PLACEBO_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Arm Label: citrate regional anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): heparin | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): citrate regional anticoagulation, heparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Arm Label: Early RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Early RRT strategy | Arm Label: Delayed RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Delayed RRT strategy | Intervention Type: PROCEDURE; Name: Early RRT strategy; Assigned to Arm(s): Early RRT strategy | Intervention Type: PROCEDURE; Name: Delayed RRT strategy; Assigned to Arm(s): Delayed RRT strategy
B: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous venvenous hemofiltration (CVVH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous venovenous hemodialysis (CVVHD) | Intervention Type: DEVICE; Name: Continuous venvenous hemofiltration (CVVH); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Continuous venovenous hemodialysis (CVVHD); Assigned to Arm(s): 2
D: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I / II Clinical Trial Regarding Vascular Regeneration Therapy by Transplantation of Autologous Peripheral Blood Endothelial Progenitor Cells (CD34+ Cells) in No-Option Patients With Chronic Critical Limb Ischemia
Brief Summary: The purpose of this study is to determine if stem cell therapy with one's own cells (autologous cells) delivered intramuscularly to one's leg with ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound.


Options:
A: Arm Label: 4times injection; Type: EXPERIMENTAL; Interventions: Biological: 4times injection | Arm Label: one injection; Type: EXPERIMENTAL; Interventions: Biological: stem cell transplantation | Intervention Type: BIOLOGICAL; Name: 4times injection; Assigned to Arm(s): 4times injection | Intervention Type: BIOLOGICAL; Name: stem cell transplantation; Assigned to Arm(s): one injection
B: Intervention Type: GENETIC; Name: Autologous peripheral blood CD34 positive cell therapy; Assigned to Arm(s): N/A
C: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC
D: Arm Label: Active/Treatment Group; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic bone marrow derived mesenchymal stem cells | Arm Label: Observation Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 3; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Group 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Allogeneic bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Active/Treatment Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Cross-over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients With Hemophilia A and Inhibitors
Brief Summary: The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.


Options:
A: Arm Label: Group 1; Type: N/A; Interventions: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Arm Label: Group 2; Type: N/A; Interventions: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Intervention Type: DRUG; Name: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Assigned to Arm(s): Group 2
B: Arm Label: Prophylaxis, high dose (trial duration 52 weeks); Type: EXPERIMENTAL; Interventions: Drug: nonacog beta pegol | Arm Label: Prophylaxis, low dose (trial duration 52 weeks); Type: EXPERIMENTAL; Interventions: Drug: nonacog beta pegol | Arm Label: On-demand (trial duration 28 weeks); Type: EXPERIMENTAL; Interventions: Drug: nonacog beta pegol | Intervention Type: DRUG; Name: nonacog beta pegol; Assigned to Arm(s): Prophylaxis, high dose (trial duration 52 weeks) | Intervention Type: DRUG; Name: nonacog beta pegol; Assigned to Arm(s): Prophylaxis, low dose (trial duration 52 weeks) | Intervention Type: DRUG; Name: nonacog beta pegol; Assigned to Arm(s): On-demand (trial duration 28 weeks)
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Recombinant Coagulation Factor IX (BeneFIX) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Recombinant Coagulation Factor IX (BeneFIX) | Intervention Type: DRUG; Name: Recombinant Coagulation Factor IX (BeneFIX); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Recombinant Coagulation Factor IX (BeneFIX); Assigned to Arm(s): B
D: Arm Label: On-demand first; Type: OTHER; Interventions: Drug: activated prothrombin complex concentrate (FEIBA) | Arm Label: Prophylaxis first; Type: OTHER; Interventions: Drug: activated prothrombin complex concentrate (FEIBA) | Intervention Type: DRUG; Name: activated prothrombin complex concentrate (FEIBA); Assigned to Arm(s): On-demand first, Prophylaxis first

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Home Based Resistance Training Program for Obese Adults With Type 2 Diabetes
Brief Summary: This study will investigate the biological and psychosocial benefits of a home-based resistance-training program for sedentary, obese adults living with type 2 diabetes.


Options:
A: Arm Label: Care Coordination; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care Coordination | Arm Label: Home Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Telemedicine | Intervention Type: BEHAVIORAL; Name: Care Coordination; Assigned to Arm(s): Care Coordination | Intervention Type: BEHAVIORAL; Name: Home Telemedicine; Assigned to Arm(s): Home Telemedicine
B: Arm Label: mWELLCARE software arm; Type: EXPERIMENTAL; Interventions: Other: mWELLCARE | Arm Label: Usual care arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: mWELLCARE; Assigned to Arm(s): mWELLCARE software arm | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care arm
C: Intervention Type: BEHAVIORAL; Name: Resistance Training; Assigned to Arm(s): N/A
D: Arm Label: Medical group visits; Type: EXPERIMENTAL; Interventions: Other: Diabetes Group Management Visits | Arm Label: Treatment as Usual control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diabetes Group Management Visits; Assigned to Arm(s): Medical group visits

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity Promotion in Breast Cancer Survivors: A Population Based Randomized Controlled Trial
Brief Summary: Over 30 studies have shown that exercise can improve physical fitness, reduce fatigue, increase functioning, and enhance overall quality of life (QoL) in breast cancer survivors both during and after treatments. Research has also shown, however, that breast cancer survivors experience a significant reduction in physical activity during treatments that is not recovered even years after treatments are completed. The objectives of this study are to examine the effects of two behavior change interventions (a step pedometer and printed materials) on physical activity, social cognitive variables, and QoL in a population-based sample of breast cancer survivors. Approximately 300 breast cancer survivors living in Northern Alberta will be randomized to one of four groups: (1) an exercise recommendation only group (viewed as the current standard of care), (2) an exercise recommendation plus pedometer group, (3) an exercise recommendation plus printed materials group, and (4) an exercise recommendation plus pedometer and printed materials group. Our primary hypothesis is that participants receiving the combined pedometer and printed materials intervention will report the greatest change in physical activity. Our secondary hypotheses are that these interventions will also result in improved QoL and more positive social cognitive beliefs about exercise in breast cancer survivors. Given the geographic dispersion of our population, finding practical and sustainable interventions that employ distance medicine-based approaches may be ideal for promoting healthy activity patterns in breast cancer survivors in Northern Alberta.


Options:
A: Arm Label: Telerehabilitation group; Type: EXPERIMENTAL; Interventions: Behavioral: Telerehabilitation group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telerehabilitation group; Assigned to Arm(s): Telerehabilitation group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2
C: Intervention Type: DEVICE; Name: Pedometer; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Exercise guidebook; Assigned to Arm(s): N/A
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Attention Control (Health Education); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control (Health Education) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Attention Control (Health Education); Assigned to Arm(s): Attention Control (Health Education)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trachoma Elimination With Repeated Mass Azithromycin Treatments
Brief Summary: The WHO has initiated a program to eliminate blinding trachoma by the year 2020, in large part by mass oral azithromycin distributions. It is not clear how frequently or for how long these treatments are necessary. Here we assess the frequency and duration of treatment.


Options:
A: Intervention Type: DRUG; Name: Mass treatment with oral azithromycin to an entire village; Assigned to Arm(s): N/A
B: Arm Label: ≥90% coverage with azithromycin target; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: 80%-89% coverage with azithromycin target; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: ≥90% coverage with azithromycin , treatment based; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: 80%-89% coverage with azithromycin : treatment based; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 80%-89% coverage with azithromycin target, ≥90% coverage with azithromycin target | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 80%-89% coverage with azithromycin : treatment based, ≥90% coverage with azithromycin , treatment based
C: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
D: Intervention Type: DRUG; Name: triple co administration at once of the combination of Albendazole + ivermectin + azithromycin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Increasing Infant Preventive Health Service Delivery in an Inner City Population
Brief Summary: The study hypothesis is that case management using patient navigators ("promatoras" in the Latino community) will increase infant immunization rates and use of well child care in an inner city population of low socioeconomic status.


Options:
A: Arm Label: Population-based Reminder/Recall; Type: EXPERIMENTAL; Interventions: Behavioral: Recall conducted centrally by local health department | Arm Label: Practice-based Reminder/Recall; Type: EXPERIMENTAL; Interventions: Behavioral: Recall conducted by private practices | Intervention Type: BEHAVIORAL; Name: Recall conducted by private practices; Assigned to Arm(s): Practice-based Reminder/Recall | Intervention Type: BEHAVIORAL; Name: Recall conducted centrally by local health department; Assigned to Arm(s): Population-based Reminder/Recall
B: Arm Label: Historical Cohort; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminder Recall Outreach; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminder-Recall-Outreach | Arm Label: Case Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Case Management | Arm Label: Patient Navigation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient Navigator | Intervention Type: BEHAVIORAL; Name: Reminder-Recall-Outreach; Assigned to Arm(s): Reminder Recall Outreach | Intervention Type: BEHAVIORAL; Name: Case Management; Assigned to Arm(s): Case Management | Intervention Type: BEHAVIORAL; Name: Patient Navigator; Assigned to Arm(s): Patient Navigation
C: Arm Label: SMS Vaccine; Type: N/A; Interventions: Behavioral: SMS message reminding mothers to come for their scheduled vaccines | Arm Label: Usual care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS message reminding mothers to come for their scheduled vaccines; Assigned to Arm(s): SMS Vaccine
D: Arm Label: mailed reminder notice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mailed influenza vaccination reminder notice | Arm Label: No reminder notice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mailed influenza vaccination reminder notice; Assigned to Arm(s): mailed reminder notice

Answer: B